(BIOLIN, NR/BB/BB)
"*BIOCON 1Q EBITDA 8.29B RUPEES, EST. 8.42B RUPEESS" - BBG
Small EBITDA miss, leverage stable, neutral for spreads.
Indian biopharmaceutical company Biocon released Q1 results overnight, reporting revenues up +15% YoY to INR39.4bn, with the Biosimilars segment (62% of revenues) outperforming at +18% YoY.
Core EBITDA for the quarter was down 53% YoY to INR 8.3bn, below consensus (INR 8.4bn). However, on a like-for-like basis excluding prior-year divestment gains, EBITDA grew +19% YoY. EBITDA margins declined to 21% from 38% in the year-ago period (and 25% in 4Q25).
Net leverage (net debt/EBITDA) was stable at 3.3x versus end-FY25. Overall neutral for spreads.
Find more articles and bullets on these widgets:
The WSJ is reporting that Kevin Hassett met with US President Trump twice during June to discuss the Fed Chair role. This comes as Trump continues to criticize current Fed Chair Powell for not cutting interest rates.
The BBDXY range overnight was 1193.28 - 1199.72, Asia is currently trading around 1197. The BBDXY had another decent bounce higher yesterday and unlike the price action over the NFP it continues to hold onto most of its gains. We have danced this dance before and the USD has most recently failed to follow through on these corrections. The market is short and vulnerable but is still quite away from pressure points. The larger picture remains one of USD weakness and in the current environment rallies should continue to be met with supply, first resistance is back towards the 1205/1215 area, a sustained break above 1220 would be needed to begin challenging the shorts conviction, that does look a long way off for now.
Fig 1: BBDXY Daily Chart
Source: MNI - Market News/Bloomberg Finance L.P